China-US Dual Filing Success:Porton Advanced’s End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors’ Innovative Oncolytic Bacteria Therapy
Porton Advanced Stem Cell Exosomes Granted INCI Status, Advancing into Global Cosmetic Ingredient Market
Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
Porton Advanced and T&L biotechnology Announce Strategic Partnership to Strengthen the Global CGT Supply Chain
Porton Advanced’s Comprehensive CDMO Service Facilitates IND Approval for CSPC’s Pioneering in vivo CAR‑T Therapy in China
Porton Advanced’s End-to-End Cell Therapy CDMO Service Accelerates NMPA Approval of Gene MiNK Biotechnology’s Innovative NK Therapy
